-
Signature
-
/s/ Alphonse Valbrune, as Attorney-in-Fact, for Sandeep Sahai
-
Issuer symbol
-
CWAN
-
Transactions as of
-
13 Jun 2025
-
Net transactions value
-
-$2,026,551
-
Form type
-
4
-
Filing time
-
16 Jun 2025, 19:58:35 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Sahai Sandeep |
Chief Executive Officer, Director |
C/O CLEARWATER ANALYTICS HOLDINGS, INC., 777 W. MAIN STREET, SUITE 900, BOISE |
/s/ Alphonse Valbrune, as Attorney-in-Fact, for Sandeep Sahai |
16 Jun 2025 |
0001879927 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CWAN |
Class A Common Stock |
Options Exercise |
$499,506 |
+113,524 |
+13% |
$4.40 |
990,278 |
13 Jun 2025 |
Direct |
|
| transaction |
CWAN |
Class A Common Stock |
Tax liability |
$1,413,492 |
-63,524 |
-6.4% |
$22.25 |
926,754 |
13 Jun 2025 |
Direct |
F1 |
| transaction |
CWAN |
Class A Common Stock |
Sale |
$1,112,565 |
-50,000 |
-5.4% |
$22.25 |
876,754 |
13 Jun 2025 |
Direct |
F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CWAN |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-113,524 |
-11% |
$0.000000 |
874,815 |
13 Jun 2025 |
Class A Common Stock |
113,524 |
$4.40 |
Direct |
F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: